Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 3/20 | 0.38 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.35 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1616932 | 1.00 | GAA (0.39) | GAATP53MAP1LC3BTSHRAGTR1 | |
| SCHEMBL1617075 | 0.86 | MAP1LC3B (0.36) | GAATP53MAP1LC3BTSHRNPC1 | |
| SCHEMBL1617077 | 0.86 | MAP1LC3B (0.36) | GAATP53MAP1LC3BTSHRNPC1 | |
| SCHEMBL1617177 | 0.81 | MAP1LC3B (0.47) | MAP1LC3BNPC1RAB9ASMN1; SMN2PBRM1 | |
| SCHEMBL1617176 | 0.81 | MAP1LC3B (0.47) | MAP1LC3BNPC1RAB9ASMN1; SMN2PBRM1 | |
| SCHEMBL1615801 | 0.78 | SLC6A2 (0.42) | SMN1; SMN2 | |
| SCHEMBL1615803 | 0.78 | SLC6A2 (0.42) | SMN1; SMN2 | |
| SCHEMBL1617137 | 0.72 | MAP1LC3B (0.44) | TP53MAP1LC3BTSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL1617107 | 0.71 | HTR2A (0.40) | SMN1; SMN2ALDH1A1HTT | |
| SCHEMBL1616878 | 0.70 | MAP1LC3B (0.47) | GAAMAP1LC3BNPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012030952-A3 | REDUCING RIPPLE CURRENT IN A SWITCHED-MODE POWER CONVERTER EMPLOYING A BRIDGE TOPOLOGY | TEXAS INSTRUMENTS INCORPORATED (US) | 2012-05-10 | — | — | WO | disclosed |
| EP-2231629-B1 | MODULATORS FOR AMYLOID BETA | HOFFMANN LA ROCHE (CH) | 2011-11-30 | — | — | EP | disclosed |
| US-7923450-B2 | Modulators for amyloid beta | HOFFMANN-LA ROCHE INC. (US) | 2011-04-12 | — | — | US | disclosed |
| EP-2231629-A1 | MODULATORS FOR AMYLOID BETA | F. Hoffmann-La Roche AG (CH) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009087127-A1 | MODULATORS FOR AMYLOID BETA | F. HOFFMANN-LA ROCHE AG (CH) | 2009-07-16 | — | — | WO | disclosed |
| US-20090181965-A1 | MODULATORS FOR AMYLOID BETA | F. HOFFMANN-LA ROCHE AG (CH) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181965-A1 | MODULATORS FOR AMYLOID BETA | APP, PSEN1, BACE1 | GAA 962/4885TP53 1297/4885MAP1LC3B 818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.